Last reviewed · How we verify
Interferon-α5 plus Interferon-α 2b
At a glance
| Generic name | Interferon-α5 plus Interferon-α 2b |
|---|---|
| Sponsor | Digna Biotech S.L. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon-α5 plus Interferon-α 2b CI brief — competitive landscape report
- Interferon-α5 plus Interferon-α 2b updates RSS · CI watch RSS
- Digna Biotech S.L. portfolio CI